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Abstract
Background—In the female genital tract, vaginal colposcopy, endometrial mucosal integrity and
inflammatory mediators are potential in vivo biomarkers of microbicide and contraceptive safety.
Study Design—A randomized, blinded crossover trial of 18 subjects comparing effects of
Gynol II (putative inflammatory gel), HEC (putative inert gel) and no gel exposure on endometrial
and vaginal epithelial integrity and endometrial and vaginal inflammatory markers (IL-1β, IL-6,
IL-8, MCP-1, MIP-1α, MIP-1β, RANTES, TNF-α, IL-1RA, IL-10, SLPI).
Results—Gynol II was associated with more vaginal lesions. No endometrial disruptions were
observed across conditions. In the vagina, RANTES (p=0.055) and IL-6 (p=0.04) were higher
after HEC exposure than at baseline. In the endometrium, IL-1β (p=0.003) and IL-8 (p=0.025)
were lower after Gynol II cycles than after no gel.
Conclusions—Gynol II and HEC may modulate inflammatory markers in the vagina and
endometrium. How these changes relate to infection susceptibility warrants further study.
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Potential vaginal contraceptives or microbicides need to demonstrate safety in vivo prior to
widespread use. Currently, methodology to measure in vivo inflammatory responses to
vaginal products is primarily limited to colposcopy to assess vaginal epithelial integrity [1–
3]. However, gross visual inspection may not detect subtle inflammatory changes induced
by vaginal products [3,4].
Multiple cytokines and chemokines are present on mucosal surfaces of the lower female
genital tract and are potential in vivo biomarkers of inflammation at these sites. Evaluation
of vaginal cytokines through vaginal lavage has been incorporated into some assessments of
candidate microbicides [4–6]. However, these initial studies need to be replicated to prove
their validity. Furthermore, the impact of microbicides on the upper genital tract, namely,
the endometrium, is largely unknown.
The overall goal of this study was to assess whether vaginal exposure to a putative
inflammatory gel (3% nonoxynol-9 vaginal gel [Gynol II]) and a putative inert gel
(hydroxyethyl cellulose gel [HEC]) can elicit significant changes in inflammatory response
or disruptions in epithelial integrity in the vagina and endometrium. Nonoxynol-9 was
selected as the positive control because it is known to induce vaginal inflammation [1,2,4]
and has been clinically linked to increasing HIV transmission [7]. HEC was selected as the
negative control because of its common use as a placebo. If consistent patterns of cytokines,
chemokines or epithelial disruptions were observed using these well-characterized gels,
these inflammatory biomarkers and their patterns of change could serve as in vivo
biomarkers of contraceptive or microbicide safety. We hypothesized that use of Gynol II
would result in greater pro-inflammatory responses and epithelial disruption in both the
vagina and endometrium than use of HEC. To test this hypothesis, we compared the effect
of the gels on 4 outcomes: 1) vaginal epithelial integrity; 2) inflammatory cytokines and
chemokines in the vagina; 3) endometrial integrity; 4) inflammatory cytokines and
chemokines in the endometrium. Furthermore, we assessed how cytokines and chemokines
differed between the vagina and endometrium.
2. Methods
A randomized, assessor-blinded, optional-crossover trial was undertaken to assess the effect
of Gynol II (Personal Products, Rariton, NJ) and/or HEC (Biosyn, Inc., Huntingdon Valley,
PA) on the vagina and endometrium. Eligible subjects were between ages 18 to 45 years,
had regular menstrual cycles between 25–35 days, were at low risk for sexually transmitted
infections, did not use intravaginal or intrauterine contraceptives, had a normal Papanicolaou
test within 6 months and abstained from vaginal intercourse during the study from the day
before first day of product use until 5 days following vaginal and endometrial assessment,
rendering the first sampling time point at least 4 days from any semen exposure. Subjects
underwent a wet prep to screen for yeast, bacterial vaginosis using Amsel’s criteria, and
trichimonas. They were also screened for herpes simplex virus (HSV0, gonorrhea and
chlamydia using PCR testing, and HIV using serum testing. Potential subjects were
excluded if she had a sexually transmitted infection, yeast infection, bacterial vaginosis,
cervicitis, endometritis, current pregnancy, fewer than 10 weeks since the end of the last
pregnancy, current breastfeeding, recent gynecologic surgery, colposcopy or endometrial
biopsy, or allergy to Gynol II or HEC. Women on hormone-based contraceptive methods
(oral, transdermal, injectable or implanted) were not excluded.
Subjects underwent at least 1 (and up to 3) sets of colposcopy, vaginal lavage (VL),
endometrial lavage (EL), and endometrial biopsy in the follicular phase of separate
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menstrual cycles, between cycle days 6 and 12. Subjects were provided with kits containing
assigned gels; study coordinators conducted teaching to demonstrate how to fill applicators
and insert the product. During cycles when subjects were exposed to gel products, the
exposure began in the early follicular phase between cycle days 3 and 9. A maximum of 1
intervening menstrual cycle between any 2 assessment cycles was allowed. The first
evaluation was performed without any gel exposure. The second evaluation was after 3
days’ use of one product. Assignment of Gynol II versus HEC at this evaluation was
randomized using a computer-generated scheme blocked to assure near-equal numbers of
cycles assigned to each gel. For individuals who underwent a third evaluation, this was
performed after 3 days’ use of the second product. Because each subject could be exposed to
two gels and sampling was designed to occur during the same part of the menstrual cycle,
this study required assessments over multiple menstrual cycles. The subject, study team and
clinician performing the evaluations were blinded to which gel was administered in a given
cycle.
Participants self-inserted a single applicator of study gel once a morning for 3 consecutive
days during the follicular phase after cessation of menses. Each Gynol II applicator
contained 150 mg of nonoxynol-9 (N-9). On the third day, the participant returned for
colposcopy, VL, EL and endometrial biopsy, in that order. Evaluations were timed to occur
1–4 h after the third gel administration. For each colposcopy, lesions and the following
findings were documented: degree of epithelial disruption, location, color, blood vessels,
and size [8].
VL was performed by introducing 5 mL of normal saline into the posterior vaginal fornix.
Saline was recovered and transferred to a tube with phosphate buffered saline (PBS). EL
was performed by injecting 2 mL of normal saline into the uterine cavity via a sterile
hysterosalpingogram catheter (Lyco, San Antonio, TX) and recovered by suction. Flushing
was performed with fresh saline up to 5 times to obtain a minimum of 4 mL of EL fluid [9].
VL and EL specimens were centrifuged at 200×g for 10 min, and supernatants were frozen
at −70°C.
Eleven inflammatory markers were selected based on presence in the vaginal epithelium or
endometrium, and/or change after exposure to N-9 [4,6,10–13]. These chemokines and
cytokines were assayed in duplicate in all VL and EL specimens (DuoSet ELISA
Development kits, R&D Systems, Minneapolis, MN) according to manufacturer guidelines.
Levels of 8 pro-inflammatory markers IL-1 β, IL-6, IL-8, MCP-1, MIP-1 α, MIP-1 β,
RANTES, and TNF-α and 3 anti-inflammatory markers IL-1RA, IL-10 and SLPI were
determined. The limits of detectability were protein levels at which no optical displacement
(OD) values were recorded. The precise limit of detectability for each cytokine is not known
but is lower than the lowest point on the standard curve. For each cytokine, the ranges of the
standard curve were as follows: IL-1β (3–300 pg/mL), IL-6 (10–200 pg/mL), IL-8 (30–3000
pg/mL), MCP-1 (15–1000 pg/mL), MIP-1α (10–200 pg/mL), MIP-1β (15–200 pg/mL),
RANTES (15–1000 pg/mL), TNF-α (10–1000 pg/mL), IL-1RA (30–3000 pg/mL), IL-10
(20–2000 pg/mL) and SLPI (60–6000 pg/mL). Samples with OD levels below the standard
curve were given 1/2 value of the lowest point on the standard curve [14]. Samples were not
diluted. Cytokines for which some samples had values above the linear range of the standard
curve are presented, but formal statistical comparisons were not performed. Means of the
duplicates were used for analysis.
Immediately following collection of endometrial lavage specimens, an endometrial biopsy
was performed with a sterile 3 mL endometrial suction curette. Tissue from endometrial
biopsies were fixed in formalin, dehydrated in ethanol, paraffin embedded and sectioned.
Hematoxylin and eosin staining was performed using the Surgipath Hematoxylin Gill III
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Formula (Surgipath, Inc, Richmond, IL, USA) according to manufacturer instructions.
Specimens were examined by a single pathologist blinded to treatment allocation. The
following findings were documented: discontinuity of uterine epithelium, hemorrhage,
necrosis of the endometrial stroma or epithelium, polymorphonuclear leukocytes (PMNs)
and other inflammatory cells and luminal debris in glands.
Categorical variables were summarized by frequencies and proportions. Continuous
variables were summarized by mean, median, and range. Paired t-test (for normally
distributed data), Wilcoxon signed-rank test (for non-normally distributed data), Test for
Symmetry and McNemar’s test were used to compare paired variables. Independent data
were compared using Student’s t-test (for normally distributed data), Wilcoxon rank-sum
test (for non-normally distributed data) and Fisher’s exact test, as appropriate. P-values
≤0.05 were considered significant.
The study sample size was determined a priori to detect a significant difference in
endometrial epithelial changes, specifically the rate of inflammation. Inflammation was
defined by the presence of moderate to many polymorphonuclear leukocytes (PMNs) and
other inflammatory cells on endometrial biopsy specimens. The sample size calculation was
performed using the equation for a dichotomous outcome assuming a 1% rate of
inflammation among HEC cycles and a 50% rate of inflammation among N-9 cycles, 1:1
randomization of Gynol II to HEC, 80% power and a two-tailed p-value of 0.05. The
calculated sample size was 14 cycles per treatment arm. The study was reviewed and
approved by the institutional review board of the University of Pennsylvania.
3. Results
Of 27 screened women, 18 subjects were enrolled at a median age of 31. years (range 22–
45). Fourteen subjects were Caucasian, 4 were African American, and 1 was Asian
American. One subject was Hispanic in addition to being African American. At study
conclusion, these 18 subjects completed 18 baseline, 14 Gynol II and 14 HEC cycles.
Twelve subjects completed baseline followed by both HEC and Gynol II cycles. Two
subjects completed baseline and HEC cycles only, and 2 subjects completed baseline and
Gynol II cycles only. Finally, 2 subjects completed only the baseline cycle. Two subjects
were on hormonal contraceptives (both combined oral contraceptive pills); both completed
baseline, Gynol II and HEC cycles. Race and ethnicity were not associated with the
likelihood of completing all three exposure cycles. Overall, participants reported minimal
complaints with respect to both gels and study procedures.
3.1. Vaginal epithelial integrity
Vaginal epithelial integrity was assessed by colposcopy. At baseline, 10 subjects had a total
of 15 lesions. During Gynol II cycles, 10 subjects had a total of 18 lesions, and in HEC
cycles, 4 subjects had a total of 5 lesions. There appeared to be more lesions after Gynol II
exposure, but the number of subjects with lesions and the number of lesions per subject were
not statistically different from baseline (p=0.27) or HEC (p=0.09) (Test for Symmetry). The
degree of epithelial disruption, diagnosis, location, color, blood vessels, and size of lesions
did not differ significantly by treatment (Table 1).
3.2. Biomarkers of inflammation: vaginal specimens
VL fluid was assayed for 8 pro-inflammatory and 3 anti-inflammatory markers. In Table 2
and Fig. 1, all data are presented. Of these, IL-1β, IL-6, IL-8, RANTES, IL-1RA and SLPI
levels had measurements above the lowest point on the standard curve. IL-1RA and SLPI
had several measurements above the assay range; formal statistical comparisons of these two
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cytokines were not performed. Most MCP-1, MIP-1a, MIP-1b, TNF-a, and IL-10 levels
were not within the linear aspects of the standard curve with this assay method. Compared
by Wilcoxon signed-rank tests, Cytokine/total protein ratios did not differ between Gynol II
and baseline. In comparing HEC to baseline cycles, RANTES (p=0.055) and IL-6 (p=0.04)
levels were significantly higher after HEC exposure.
3.3. Endometrial integrity
In endometrial biopsy specimens across all three conditions, there were no findings of
uterine epithelial discontinuity, hemorrhage, necrosis, or luminal debris (Table 3). There
were few PMNs visualized in most specimens, and this observation did not differ by
treatment (Test for Symmetry). Qualitatively, PMNs in the Gynol II and HEC cycles tended
to be peri-glandular compared to baseline cycles.
3.4. Biomarkers of inflammation: endometrial specimens
Inflammatory markers in EL fluid are summarized in Table 4 and Fig. 2, where all data are
presented. Of these, IL-1β, IL-6, IL-8, RANTES and IL-1RA levels had measurements
above the lowest point on the standard curve. IL-6, RANTES and IL-1RA had several
measurements above the assay range; formal statistical comparisons of these three cytokines
were not performed. Most MCP-1, MIP-1a, MIP-1b, TNF-a, IL-10 and SLPI levels were not
consistently within the linear range of the standard curves with this assay method. Exposure
to Gynol II was associated with lower IL-1β (p=0.003) and lower IL-8 (p=0.025). In the
endometrium, measured cytokine/total protein ratios did not differ between HEC and
baseline cycles.
3.5. Endometrial versus vaginal inflammatory markers
Finally, to assess for potential differences in immune response in the vagina versus
endometrium, we compared baseline IL-1β and IL-8 between the vagina and endometrium
(Tables 2, 4). In the endometrium, IL-1β levels were lower (p=0.02) than in the vagina.
4. Discussion
The overarching goal of this exploratory study was to examine in vivo the effects of two
well-characterized, vaginally-applied gels on the vagina and endometrium. In hopes of
characterizing an in vivo model for testing future vaginal microbicides and contraceptives,
we compared gross breaches in vaginal epithelium, endometrial histopathology and vaginal
and endometrial levels of inflammatory cytokines and chemokines after no treatment and
exposure to Gynol II and HEC gels. As expected, Gynol II appeared to induce more vaginal
epithelial lesions than control conditions. However, the experimental conditions did not
result in any gross histologic changes or specific patterns of inflammatory cells in the
endometrium. Of 11 inflammatory markers that were measured, multiples chemokines and
cytokines were not consistently detectable with this assay method. Of measurable markers
HEC exposure was associated with a rise in two pro-inflammatory molecules RANTES and
IL-6 in the vagina. In the endometrium, Gynol II exposures reduced levels of IL-1β and IL-8
The objective of testing inflammatory biomarkers in the lower genital tract after exposure to
N-9 was to confirm prior studies and delineate specific patterns of inflammatory response to
this product in the vagina and endometrium. In the vagina, none of the pro-inflammatory
measures that were hypothesized to increase after N-9 exposure exhibited a significant rise
above baseline. These study findings are not completely consistent with prior works
[4,15,16] and may have resulted from the lack of a standard approach in sampling timing,
lavage volume, duration of N-9 exposure, study size and technical differences in assays.
While sampling in this study may have occurred earlier than prior studies and missed a later
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increase in inflammatory response, subjects had already been exposed to two consecutive
daily doses of the study gel prior to the last dose and sampling. We are unable to rule out the
possibility that earlier sample resulted in interference of assays by the vehicle gels. Prior
studies have reported decrease of IL-1RA and no increase of pro-inflammatory mediators in
vaginal washings after one dose of Gynol II [4]. These findings are corroborated by the
present study. Delayed proinflammatory responses have been reported after multiple doses
of Gynol, which could not be confirmed in the present study. Technical differences such as
different ELISA kits and laboratories could also contributed to disparate findings between
the two studies. Because a recent study evaluating IL-1β and IL-6 cytokine measurements
found significant differences among ELISAs and laboratories [17], there may be a need for
conversion coefficients among different immunoassays to facilitate comparing results
among studies. Finally, while participants were asked to abstain from vaginal intercourse for
at least 4 days before each endometrial and vaginal sampling, we did not assess for the
presence of semen in the vaginal fluid, which may impact cytokine levels.
Assessing in vivo endometrial cytokines was novel. First, we noted that at least one baseline
cytokine profile differed significantly between the vagina and the endometrium, as IL-1β
levels was higher in the vagina. This analysis using cytokine/total protein ratios suggests
that the cytokine profile differs by anatomic site in the lower genital tract. Unfortunately, we
did not obtain cellular pellets of VL and EL samples to further account for differences in
sampling volume. We found the reduction of two pro-inflammatory cytokines IL-1β and
IL-8 in endometrial lavage samples after N-9 exposure in the setting of no epithelial
disruption on histology. This observation may reflect more subtle toxicity that was not
observed by gross histology. Alternatively, although the number of washings required to
obtain 2 mL of endometrial lavage fluid was 2 for the majority of cycles, it is possible that
variable numbers of washings may “dilute” cytokines. Changes in cytokine/chemokine
profile in the human endometrium after N-9 exposure have also been documented by two ex
vivo studies. The first of these used ex vivo human endometrial explants and also
demonstrated falls in pro-inflammatory measures IL-1β, TNF-α, and IL-8 after N-9
exposure [13]. However, these observations may reflect cellular necrosis and a lack of
inflammatory cells to produce cytokines after exposure to N-9. Similarly, an in vitro dual-
chamber model using a human endometrial cancer cell line (HEC-1A) demonstrated that
high doses of N-9 was associated with decreases in IL-8, MCP-1 and SLPI, but lower doses
induced IL-8 [18]. Lower doses of N-9 also reduced secretion of the pro-inflammatory
mediator MCP-1 and anti-inflammatory mediator SLPI. Although these data from Gali et al.
support dose-dependent effects of N-9, the effect of lower doses on the immunomodulatory
markers in their model is not entirely consistent. These early data support future studies
assessing the in vivo response to vaginal products in both the vagina and endometrium, but
careful consideration of study design to yield consistent, reproducible data is warranted.
The placebo exposure HEC was associated with significant increases in two
proinflammatory chemokines (RANTES and IL-6) in the vagina. In the vagina, prior murine
and ex vivo human vaginal epithelium studies have not identified cytokine changes after
HEC exposure [16,19]. There have not been other previous in vivo human studies of the
effect of HEC on these biomarkers. Our results need to be interpreted with caution.
However, if replicated, this study suggests that HEC is not an “inert” gel and may not be the
optimal “placebo” control in future studies.
Finally, endometrial histology by light microscopy was not a sensitive test for detecting
differences in the endometrium after exposure to the test conditions. Histology was
evaluated because prior work documented rapid movement of N-9 into the upper female
reproductive tract after vaginal insertion [20]. Further, mouse and human explant models
show histological changes with N-9 exposure [13,21]. In this study, light microscopy
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detected no significant histologic changes or patterns of inflammatory cells in the
endometrium. Potential future directions include examining these samples by electron
microscopy.
In conclusion, this trial demonstrated that cytokines and chemokines are altered by exposure
to Gynol II and HEC, but the observed patterns of change are not entirely consistent with
prior reports. Overall, in vivo studies of these molecular markers in the lower genital tract
have been few with small sample sizes. Given limited evidence, more human data will be
needed to determine whether biomarkers of inflammatory response are good surrogates of
microbicide and contraceptive safety. Specifically, the methodology for obtaining vaginal
specimens ought to be more uniform and future work may benefit from universal controls.
Finally, future work with larger sample sizes is needed to determine how these changes
relate to infection susceptibility and their utility in clinical studies.
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Figure 1*. Comparisons ** of vaginal cytokine/total protein ratios by exposure
* Box-Plots: Boxes depict the median (middle horizontal line), 25th percentile (lower
horizontal border) and 75th percentile (higher horizontal border). Whiskers (distal ends of
vertical lines) depict 5th and 95th percentiles.
** Wilcoxon signed-ranktests. For MCP-1, MIP-1α, MIP-1β TNFα, IL-10, measurements
below lowest point on standard curve; no formal statistical comparisons were performed.
For IL-1RA and SLPI, proportion of measurements above the highest point on the standard
curve; no formal statistical comparison were performed.
*** RANTES (p = 0.055) and IL-6 (0.04) levels were significantly higher in HEC cycles
than at Baseline
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Figure 2*. Comparisons** of endometrial cytokine/total protein ratios by exposure
* Box-Plots: Boxes depict the median (middle horizontal line), 25th percentile (lower
horizontal border) and 75th percentile (higher horizontal border). Whiskers (distal ends of
vertical lines) depict 5th and 95th percentiles.
** Wilcoxon signed-ranktests. For MCP-1, MIP-1α, MIP-1β TNF α, IL-10, measurements
below lowest point on standard curve; no formal statistical comparisons were performed.
For IL-6, RANTES and IL-1RA, a proportion of measurements were above the highest point
on the standard curve; no formal statistical comparison were performed.
*** IL-1β (p=0.003) and IL-8 (p=0.025) were significantly lower with Gynol II exposure
than at Baseline
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  Intact 12 (80%) 3 (60%) 15 (83%)
  Superficial disruption 3 (20%) 2 (40%) 3 (17%)
  Deep disruption 0 0 0
Diagnosis
  Erythema 7 (46%) 2 (40%) 10 (55%)
  Petechiae 5 (33%) 1 (20%) 3 (17%)
  Abrasion 1 (7%) 1 (20%) 1 (6%)
  Other 1 (7%) 1 (20%) 2 (11%)
Location
  External genitalia 7 (46%) 2 (40%) 7 (39%)
  Cervix 7 (46%) 2 (40%) 11 (61%)
  Vagina 1 (7%) 1 (20%) 0
Color
  Normal 0 0 0
  Slightly red 6 (39%) 2 (40%) 10 (56%)
  Red 8 (54%) 3 (60%) 6 (33%)
  White 1 (7%) 0 2 (11%)
Blood vessels
  Intact 8 (54%) 2 (40%) 12 (67%)
  Disrupted 7 (46%) 3 (60%) 6 (33%)
Size
  <5 mm 7 (46%) 3 (60%) 5 (28%)
  5–10 mm 4 (27%) 2 (40%) 5 (28%)
  >10 mm 4 (27%) 0 8 (44%)
*
18 Baseline, 14 HEC and 14 Gynol II colposcopies were performed.
**
McNemar’s tests used to compare lesions by exposure group
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Table 2







IL-1β 0.1 (0.003–1.0) 0.11 (0.0004–28.7) 0.03 (0.0009–6.98)
IL-6** 0.14 (0.06–0.59) 0.30 (0.06–0.96) 0.08 (0.01–0.25)
IL-8 1.27 (0.13–4.3) 0.97 (0.16–22.5) 0.81 (0.09–16.6)
MCP-1 0.018 (0.004–0.92) 0.065 (0.001–2.53) 0.007 (0.0005–0.66)
MIP-1α 0.023 (0.008–0.067) 0.029 (0.01–0.11) 0.012 (0.002–0.069)
MIP-1β 0.098 (0.012–0.46) 0.09 (0.025–0.33) 0.041 (0.01–0.53)
RANTES** 0.21 (0.04–0.49) 0.24 (0.10–1.03) 0.16 (0.02–0.87)
TNF-α 0.04 (0.005–0.17) 0.02 (0.002–0.12) 0.04 (0.02–0.3)
IL-1RA 52.0 (1.56–584) 61.3 (0.42–1365.5) 27.5 (1.04–221.3)
IL-10 0.06 (0.01–0.14) 0.074 (0.03–0.34) 0.04 (0.005–0.11)
SLPI 76.8 (15.3–176.9) 100.4 (44.3–379.6) 44.7 (1.84–274.7)
*
Wilcoxon signed-rank tests. For MCP-1, MIP-1α, MIP-1β, TNFα, IL-10, measurements below lowest point on standard curve; no formal
statistical comparisons were performed. For IL-1RA and SLPI, a proportion of measurements above the highest point on the standard curve; no
formal statistical comparisons were performed.
**
RANTES (p=0.055) and IL-6 (0.04) levels were significantly higher in HEC cycles than at Baseline
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Table 3







Discontinuity of uterine epithelium 0 0 0
Hemorrhage 0 0 0
Regeneration of uterine epithelium
  Proliferative 16 (89%) 12 (86%) 12 (86%)
  Secretory 1 (5%) 0 1 (7%)
  Interval 1 (5%) 1 (7%) 0
  Not sufficient 0 1 (7%) 1 (7%)
Necrosis of endometrial stroma or epithelium 0 0 0
Polymorphonuclear leukocytes (PMNs) and other inflammatory cells
  Absent 5 (28%) 3 (21%) 1 (7%)
  Few 10 (56%) 8 (57%) 12 (86%)
  Moderate 3 (16%) 3 (21%) 1 (7%)
  Many 0 0 0
Luminal debris in glands 0 0 0
*
McNemar’s test and Test of Symmetry used to compare lesions by exposure group
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Table 4







IL-1β 0.05 (0.01–0.85) 0.05 (0.0007–10.3) 0.02 (0.005–0.08)
IL-6 0.10 (0.017–2.02) 0.06 (0.004–1.96) 0.053 (0.011–1.39)
IL-8 0.22 (0.02–8.9) (0.53 (0.11–147.6) 0.09 (0.02–6.0)
MCP-1 0.044 (0.007–5.93) 0.25 (0.008–6.44) 0.036 (0.008–1.32)
MIP-1α 0.032 (0.005–0.11) 0.048 (0.001–0.18) 0.039 (0.006–0.25)
MIP-1β 0.083 (0.014–0.26) 0.089 (0.002–1.14) 0.09 (0.012–0.41)
RANTES 0.79 (0.055–1.74) 0.54 (0.011–9.76) 0.88 (0.069–2.83)
TNF-α 0.064 (0.003–0.15) 0.032 (0.0007–0.25) 0.05 (0.005–0.19)
IL-1RA 0.69 (0.23–12.8) 1.9 (0.065–286.7) 0.35 (0.069–3.74)
IL-10 0.11 (0.004–0.74) 0.098(0.005–0.23) 0.11 (0.006–0.42)
SLPI 117.5 (4.61–598.2) 94.3 (3.5–298.9) 97.8 (6.95–439.3)
*
Wilcoxon signed-rank tests. For MCP-1, MIP-1α, MIP-1β, TNF α, IL-10 and SLPI, measurements below lowest point on standard curve; no
formal statistical comparisons were performed. For IL-6, RANTES and IL-1RA, a proportion of measurements were above the highest point on the
standard curve; no formal statistical comparisons were performed.
**
IL-1β (p=0.003) and IL-8 (p=0.025) were significantly lower with Gynol II exposure than at Baseline
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